Asunra100 mg

Asunra is an orally active iron-chelating agent. Its evidence-based indications are as follows:

Established / FDA-approved uses

• Chronic iron overload due to blood transfusions (transfusional hemosiderosis): Indicated in patients aged 2 years and older who have received repeated blood transfusions (e.g., for thalassemia, sickle cell disease, myelodysplastic syndromes, or other chronic anemias), typically when the patient has received at least 100 mL/kg of packed red blood cells and serum ferritin is consistently greater than 1,000 mcg/L.
• Chronic iron overload in non-transfusion-dependent thalassemia (NTDT) syndromes: Indicated in patients aged 10 years and older with liver iron concentration (LIC) of at least 5 mg Fe/g dry weight and serum ferritin greater than 300 mcg/L.

Not established / limitations

• The safety and effectiveness of Asunra used together with other iron chelation therapies have not been established; combination chelation is considered an off-label, specialist-directed approach used only in select refractory cases under close hematology supervision.
• Asunra is not indicated for acute iron poisoning/acute iron intoxication.

Deferasirox is available as film-coated tablets (commonly 90 mg, 180 mg, and 360 mg) and, in some markets, as dispersible tablets or granules for oral suspension (commonly 125 mg, 250 mg, and 500 mg strengths). Each formulation contains Deferasirox as the active pharmaceutical ingredient along with pharmaceutically acceptable excipients; the exact strength and formulation available should be confirmed on the product label/pack insert.

Asunra is a synthetic, orally administered iron-chelating agent (tridentate ligand) used for the management of chronic iron overload. Unlike older parenteral chelators, Asunra can be taken by mouth once daily, which has made it a widely used option for long-term iron chelation therapy, particularly in patients who require repeated blood transfusions.

Asunra carries boxed warnings for renal toxicity (including acute kidney injury and Fanconi syndrome), hepatic toxicity (including hepatic failure), and gastrointestinal hemorrhage, and therefore requires careful patient selection and regular laboratory monitoring throughout treatment.

Asunra belongs to the therapeutic class of iron-chelating agents, used in the management of chronic transfusional and non-transfusional iron overload.

Mechanism / Pharmacodynamics

Deferasirox is a tridentate ligand that binds iron with high affinity in a 2:1 (Deferasirox:iron) ratio, forming a stable complex with ferric iron (Fe3+). The iron-Deferasirox complex is excreted predominantly in the feces (via bile), with only a small fraction eliminated renally. Iron excretion with Deferasirox is dose-dependent.

Pharmacokinetics

• Absorption: Peak plasma concentration (Tmax) is typically reached 1.5 to 4 hours after an oral dose; taking Deferasirox with a high-fat meal can increase exposure, so it is generally taken on an empty stomach or with a light meal.
• Metabolism: Mainly through glucuronidation (UGT1A1 and UGT1A3), with a minor contribution from CYP3A4/CYP2C8-mediated oxidative metabolism.
• Elimination: Predominantly fecal/biliary excretion (majority of the dose); a small proportion (~8%) is excreted renally.

• Take Asunra once daily, at approximately the same time each day, on an empty stomach or with a light meal (avoid a high-fat meal, which can increase absorption unpredictably).
• Film-coated tablets should be swallowed whole with water; they may also be crushed and sprinkled on soft food (such as yogurt or apple sauce) immediately before use, if swallowing whole tablets is difficult.
• Dispersible tablets/granules (where used) should be dispersed completely in water, orange juice, or apple juice and the resulting suspension taken immediately; do not chew or swallow dispersible tablets whole.
• Do not take Asunra together with aluminum-containing antacids.
• Do not stop or change the dose of Asunra on your own; regular blood tests (renal function, liver function, ferritin) are required throughout treatment.

Asunra is involved in several clinically significant drug interactions:

• Aluminum-containing antacids: Should not be taken together with Asunra, as aluminum may compete with the chelation process; avoid concurrent use.
• CYP3A4 substrates (e.g., hormonal contraceptives, cyclosporine, tacrolimus, simvastatin, midazolam): Asunra induces CYP3A4 and may reduce the plasma concentration and effectiveness of these drugs; hormonal contraceptives may become less effective, so non-hormonal contraception is recommended during Asunra therapy.
• CYP2C8 substrates (e.g., repaglinide): Asunra inhibits CYP2C8 and can increase repaglinide exposure, raising the risk of hypoglycemia; concurrent use should be avoided or repaglinide dosing closely monitored.
• CYP1A2 substrates (e.g., theophylline): Asunra inhibits CYP1A2 and can increase theophylline levels; concurrent use with theophylline should generally be avoided due to theophylline's narrow therapeutic index.
• Strong UGT inducers (e.g., rifampicin, phenytoin, phenobarbital, ritonavir): May reduce Asunra exposure and effectiveness; a dose increase of Asunra may be considered if co-administration cannot be avoided.
• Bile acid sequestrants (e.g., cholestyramine): May reduce absorption/exposure of Asunra.
• Busulfan: Asunra may increase busulfan exposure; monitor busulfan levels closely if used concurrently.
• NSAIDs, corticosteroids, oral bisphosphonates, or anticoagulants: Concurrent use with Asunra may increase the risk of gastrointestinal ulceration or bleeding (see Precautions and Warnings).

The following side effects have been reported with Asunra:

Common side effects

• Diarrhea, nausea, vomiting, abdominal pain
• Skin rash
• Increase in serum creatinine
• Proteinuria

Serious side effects (seek medical attention promptly)

• Signs of kidney injury (reduced urine output, swelling, unusual fatigue) - see Precautions and Warnings
• Signs of liver injury (yellowing of the skin/eyes, dark urine, severe abdominal pain) - see Precautions and Warnings
• Signs of gastrointestinal bleeding (black or bloody stools, vomiting blood, severe stomach pain) - see Precautions and Warnings
• Signs of low blood counts (unusual bruising/bleeding, persistent fever, severe fatigue) suggesting bone marrow suppression
• Signs of a severe allergic or skin reaction (facial/throat swelling, difficulty breathing, widespread blistering rash)
• Hearing changes or visual disturbances with long-term use

Pregnancy: There is limited human data on the use of Asunra in pregnancy. Animal studies have shown adverse effects on offspring at maternal doses relevant to human exposure. Asunra should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus; always consult a physician before use in pregnancy.

Lactation: Asunra and its metabolites pass into the milk of lactating animals, and effects on a nursing infant cannot be ruled out. Breastfeeding is generally not recommended during treatment with Asunra; consult a physician to weigh the benefits of breastfeeding against potential infant risk.

Contraception: Asunra may reduce the effectiveness of hormonal contraceptives (see Interactions); women of reproductive potential should use a non-hormonal method of contraception during treatment.

Boxed warnings

• Renal toxicity: Asunra can cause acute kidney injury, including renal failure requiring dialysis and renal tubular disorders (Fanconi syndrome), in some cases fatal. Assess renal function (serum creatinine on two occasions, and eGFR) before starting, then weekly for the first month and monthly thereafter. Interrupt therapy during acute illness with volume depletion.
• Hepatic toxicity: Asunra can cause hepatic injury, including hepatic failure, in some cases fatal, more common in patients with pre-existing significant hepatic impairment. Check liver enzymes and bilirubin before starting, every 2 weeks for the first month, then monthly.
• Gastrointestinal hemorrhage: Asunra can cause gastrointestinal ulceration and hemorrhage, including fatal cases, particularly in elderly patients, those with advanced hematologic malignancies, or low platelet counts, and with concurrent use of NSAIDs, corticosteroids, oral bisphosphonates, or anticoagulants.

Other precautions

• Bone marrow suppression: Neutropenia, agranulocytosis, worsening anemia, and thrombocytopenia have been reported, in some cases fatal; monitor blood counts regularly.
• Hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis and angioedema, have occurred, usually within the first month of treatment; do not restart Asunra in a patient with a prior hypersensitivity reaction.
• Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported; discontinue immediately if a severe skin reaction is suspected.
• Auditory and ocular effects: High-frequency hearing loss and lens opacities (cataracts) have been reported with long-term use; baseline and annual auditory and ophthalmic examinations are recommended.
• Overchelation: In pediatric patients particularly, chelation doses that are too high relative to actual iron burden (reflected by a low or rapidly falling ferritin) increase the risk of renal toxicity; dose should be reduced or interrupted accordingly.
• Asunra should be taken exactly as prescribed; do not stop, change, or skip doses without consulting your physician, and attend all scheduled monitoring blood tests.

Overdose of Asunra has been associated with gastrointestinal upset (nausea, diarrhea) at lower levels of excess, and with more serious hepatic and renal toxicity (including reversible hepatitis, Fanconi syndrome, and acute renal failure) at higher or prolonged excess doses. There is no specific antidote for Asunra overdose.

If an overdose is suspected, seek immediate medical attention or contact a poison control center. Management is supportive and may include induction of vomiting or gastric lavage if performed soon after ingestion under medical supervision, along with close monitoring of renal and hepatic function.

Store at room temperature (below 30°C), away from light and moisture, in the original container. Keep out of reach of children.

Renal impairment

Asunra is contraindicated if eGFR is below 40 mL/min/1.73 m2. For eGFR 40-60 mL/min/1.73 m2, start at approximately half the usual dose with close monitoring of renal function.

Hepatic impairment

No dose adjustment is needed for mild impairment (with closer monitoring); reduce the starting dose by approximately 50% for moderate impairment; avoid use in severe hepatic impairment.

Elderly patients

Elderly patients, particularly those with advanced hematologic malignancies or low platelet counts, have a higher frequency of adverse reactions, including gastrointestinal bleeding; use a conservative starting dose and monitor closely.

Pediatric patients

See Pediatric Uses for approved age ranges. Children may be at higher risk of renal toxicity, particularly with overchelation; monitor growth, renal function, and hearing/vision closely during long-term use.

Asunra is generally used long-term, for as long as the patient continues to require iron chelation (i.e., while transfusion therapy continues, or while iron overload persists in non-transfusion-dependent thalassemia). Treatment duration and continued need are guided by serial serum ferritin measurements (and, where available, liver iron concentration by MRI), performed approximately every 3-6 months, with dose interruption if iron burden falls below target thresholds. Do not stop or restart Asunra without your physician's guidance.

Deferasirox belongs to the class of oral iron-chelating agents (chelators of ferric iron).

Deferasirox is a tridentate iron chelator that binds ferric iron (Fe3+) with high affinity in a 2:1 (Deferasirox:iron) ratio. By forming a stable complex with excess iron, Deferasirox facilitates its removal from the body, predominantly through fecal excretion via the bile, thereby reducing tissue iron burden over time in patients with chronic iron overload.

Transfusional iron overload: Asunra is approved for use in children aged 2 years and older, dosed on a weight (mg/kg) basis identical to adults. Safety and efficacy in children younger than 2 years have not been established.

Non-transfusion-dependent thalassemia (NTDT): Asunra is approved for use in children aged 10 years and older meeting specific liver iron concentration and ferritin criteria. Safety and efficacy in children younger than 10 years with NTDT have not been established.

Pediatric patients require closer monitoring for renal toxicity, growth, and overchelation, as children have shown a higher rate of renal adverse effects in clinical registries. Interrupt therapy during acute illnesses associated with dehydration or volume depletion.